Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis/Speedel’s Tekturna-Diuretic Combination Clears FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Fixed-dose blood pressure pill will reach market in early February, Novartis tells “The Pink Sheet” DAILY.
Advertisement

Related Content

Tekturna Combinations Targeted To Jumpstart Renin Inhibitor’s Sales
Tekturna Combinations Targeted To Jumpstart Renin Inhibitor’s Sales
Tekturna Shows Non-Inferiority To Merck’s Cozaar On Left Ventricular Hypertrophy
Tekturna Shows Non-Inferiority To Merck’s Cozaar On Left Ventricular Hypertrophy
Speedel CEO Alice Huxley: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Phase III Tekturna Diabetes Data Could Further Differentiate Drug From Competing Hypertension Products
Novartis Files Tekturna/Hydrochlorothiazide Combination For Blood Pressure
Novartis’ Tekturna Is First Renin Inhibitor Approved For Hypertension
Novartis’ Tekturna Is First Renin Inhibitor Approved For Hypertension

Topics

Advertisement
UsernamePublicRestriction

Register

PS066766

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel